Search

Your search keyword '"Rottem M"' showing total 190 results

Search Constraints

Start Over You searched for: Author "Rottem M" Remove constraint Author: "Rottem M"
190 results on '"Rottem M"'

Search Results

55. Use of an autologous reaction in vitro to assess contributions of T and B lymphocytes to immune hyperreactivity of atopics.

56. Takayasu arteritis.

57. Wegener granulomatosis: an analysis of 158 patients.

58. Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5)

59. Endothelins belong to the assortment of mast cell-derived and mast cell-bound cytokines

60. ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle

67. Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology

68. Management of anaphylaxis due to COVID-19 vaccines in the elderly

69. WITHDRAWN: Scaling up strategies of the Chronic Respiratory Disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3 – Area 5)

70. ARIA‐EAACI care pathways for allergen immunotherapy in respiratory allergy

71. Nrf2-interacting nutrients and COVID-19: time for research to develop adaptation strategies

72. ARIA���EAACI statement on asthma and COVID���19 (June 2, 2020)

73. Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases: Review

74. MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis

75. Concepts for the Development of Person-Centered, Digitally Enabled, Artificial Intelligence-Assisted ARIA Care Pathways (ARIA 2024).

76. Genotype-Phenotype Correlations in Chronic Granulomatous Disease: Insights From a Large National Cohort.

77. Management of anaphylaxis due to COVID-19 vaccines in the elderly.

78. Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold: An ARIA-EAACI-GA 2 LEN consensus.

79. ARIA-EAACI care pathways for allergen immunotherapy in respiratory allergy.

80. ARIA-EAACI statement on asthma and COVID-19 (June 2, 2020).

81. ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice.

82. International expert consensus on the management of allergic rhinitis (AR) aggravated by air pollutants: Impact of air pollution on patients with AR: Current knowledge and future strategies.

83. Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases.

84. ARIA pharmacy 2018 "Allergic rhinitis care pathways for community pharmacy": AIRWAYS ICPs initiative (European Innovation Partnership on Active and Healthy Ageing, DG CONNECT and DG Santé) POLLAR (Impact of Air POLLution on Asthma and Rhinitis) GARD Demonstration project.

85. Burkholderia gladioli-associated facial pustulosis as a first sign of chronic granulomatous disease in a child - Case report and review.

86. Long-term outcomes following baked milk-containing diet for IgE-mediated milk allergy.

87. [RECOMMENDATION FOR EVALUATION AND TREATMENT OF CHRONIC URTICARIA - THE ISRAELI ASSOCIATION FOR ALLERGY AND CLINICAL IMMUNOLOGY].

88. Chronic granulomatous disease: Clinical, functional, molecular, and genetic studies. The Israeli experience with 84 patients.

89. International Consensus (ICON): allergic reactions to vaccines.

90. Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5).

91. [SEAFOOD ALLERGY IN ISRAEL].

92. Meteorological conditions, climate change, new emerging factors, and asthma and related allergic disorders. A statement of the World Allergy Organization.

93. Atopy and Asthma in Migrants: The Function of Parasites.

94. Subcutaneous immunotherapy in Northern Israel: efficacy and safety.

95. Omalizumab therapy for chronic spontaneous urticaria: the Israeli experience.

96. Evolutionary immune response to conserved domains in parasites and aeroallergens.

97. Omalizumab reduces corticosteroid use in patients with severe allergic asthma: real-life experience in Israel.

98. Climate change, migration, and allergic respiratory diseases: an update for the allergist.

99. [Chronic rhinitis--clinical guidelines 2010].

100. [Allergic rhinitis and its impact on asthma].

Catalog

Books, media, physical & digital resources